États-Unis · Agences & temps réel · PR Newswire

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Publié par PR Newswire · États-Unis il y a 1 h

64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

À lire aussi

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Houthi strikes on Saudi Arabia show the Yemeni rebels’ growing strength

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Partager

À lire aussi

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Houthi strikes on Saudi Arabia show the Yemeni rebels’ growing strength

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows